Skip to main content
. 2021 Feb 5;29(3):904–907. doi: 10.1016/j.ymthe.2021.02.001

Figure 1.

Figure 1

Interaction of Naturally Occurring, Unmodified Viruses and “Designer” Oncolytic Viruses with Blood Factors and Cells of Innate Immunity after Intravenous Administration

Engineering the virion surface of oncolytic viruses enables their resistance to inactivation by blood factors, reduces virus sequestration in phagocytic cells of the innate immune system, and improves their safety profile and therapeutic efficacy after intravenous administration.